INmune Bio, Inc.
NASDAQ:INMBBiotechnology
+$0.15 today
- Market cap
- $50.25M
- Beta
- 0.98
- P/E (TTM)
- -1.1
- EPS (TTM)
- -$1.56
Volume 0.09M
Average 0.68M
INMB Stock-Based Compensation
Employee pay granted in shares or options; a non-cash expense that dilutes existing shareholders.
INmune Bio, Inc.NASDAQ: INMB
Stock-Based Compensation · Q1 FY2026 · quarter ended Mar 2026
Stock-based compensation declines year over year
Q1 FY2026 stock-based compensation of $1.5M fell 27.9% year over year, ahead of the -107.3% change in trailing-twelve-month stock-based compensation. Over 3 fiscal years it compounded at +11.5% a year.
Context
- Stock-based compensation amounted to 19820.0% of revenue in FY2025, down 34501.4 pp from a year earlier.
- Stock-based compensation increased in 3 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth of -27.9% holds above the trailing-twelve-month pace of -107.3%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Stock-Based Compensation history
USD · from the cash flow
- Latest · FY2025
- 9.91M USD
- Year-over-year change
- +30.3%
- 4-year CAGR
- +19.9%
| Period | Period end | Stock-Based Compensation | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 9.91M | +30.3% |
| FY2024 | 2024-12-31 | 7.61M | +3.2% |
| FY2023 | 2023-12-31 | 7.37M | +3.1% |
| FY2022 | 2022-12-31 | 7.15M | +49.1% |
| FY2021 | 2021-12-31 | 4.8M | — |
Stock-Based Compensation vs competitors
How INMB compares with its peers on the latest reported figures
- INMB's LTM Mar 2026 stock-based compensation of $579K is the smallest of the 4 companies compared; the peer median is $3.78M.
- Its year-over-year change of -107.3% is the 3rd highest of 4, against a peer median of +38.1%.
- Over three fiscal years its annual growth of +11.5% compares with a peer median of +523.5%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $1.79B | -27809.6% | +824.6% | — | |
OKUROnKure Therapeutics, Inc. | LTM Mar 2026 | $11.67M | +86.0% | +523.5% | — |
| LTM Mar 2026 | $3.78M | +38.1% | -6.1% | 41.9% | |
| LTM Mar 2026 | $579K | -107.3% | +11.5% | — | |
| Peer median (excluding INMB) | $3.78M | +38.1% | +523.5% | 41.9% | |
Competitors are the stored peer set for INMB. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (30.34M) | (27.3M) | (30.01M) | (42.08M) | (45.93M) |
| Depreciation & Amortization | 0 | 0 | 0 | 0 | 84K |
| Deferred Income Tax | 0 | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 4.8M | 7.15M | 7.37M | 7.61M | 9.91M |
| Change in Working Capital | (3.09M) | (2.86M) | 10.44M | 1.04M | (2.53M) |
| Accounts Receivables | (3.71M) | (2.96M) | 6.02M | 1.03M | (3.13M) |
| Inventory | 3.71M | 2.96M | 0 | 0 | 0 |
| Accounts Payables | 2.26M | 1.4M | 2.72M | (1.37M) | 1.86M |
| Other Working Capital | (5.35M) | (4.27M) | 1.7M | 1.38M | (1.25M) |
| Other Non-Cash Items | 126K | 328K | 224K | 79K | 15.89M |
| Operating Cash Flow | (28.5M) | (22.69M) | (11.98M) | (33.36M) | (22.58M) |
| Capital Expenditures | (15M) | 0 | 0 | 0 | (1.04M) |
| Acquisitions (Net) | 0 | 0 | 0 | 0 | 0 |
| Purchases of Investments | 0 | 0 | 0 | 0 | 0 |
| Sales of Investments | 0 | 0 | 0 | 0 | 0 |
| Other Investing Activities | 0 | 0 | 0 | 0 | 0 |
| Investing Cash Flow | (15M) | 0 | 0 | 0 | (1.04M) |
| Debt Repayment | 14.95M | 0 | (5M) | (10M) | 0 |
| Common Stock Issued | 80.25M | 699K | 775K | 27.79M | 27.61M |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 1.15M | 30K | 0 | 422K | 0 |
| Financing Cash Flow | 96.36M | 729K | (4.23M) | 18.21M | 27.61M |
| Effect of Forex Changes | (10K) | (700K) | (100K) | 224K | (159K) |
| Net Change in Cash | 52.84M | (22.66M) | (16.31M) | (14.93M) | 3.83M |
| Free Cash Flow | (43.5M) | (22.69M) | (11.98M) | (33.36M) | (23.62M) |
INmune Bio, Inc.
NASDAQ:INMB
Intrinsic Alpha fair value
Locked
Current Price
$1.89
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.